Thrombocytopenia associated with the use of anti-tumor necrosis factor-α agents for psoriasis

被引：24

作者：

Brunasso, Alexandra Maria Giovanna ^{[2
,3
]}

Massone, Cesare ^{[1
]}

机构：

[1] Med Univ Graz, Dept Dermatol, A-8036 Graz, Austria

[2] Galliera Hosp, Dept Dermatol, Genoa, Italy

[3] Univ Florence, Sch Med, Dept Dermatol Sci, I-50121 Florence, Italy

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2009年 / 60卷 / 05期

关键词：

adalimumab; efalizumab; etanercept; infliximab; psoriasis; thrombocytopenia; DRUG-INDUCED THROMBOCYTOPENIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CROHNS-DISEASE; PHASE-III; ETANERCEPT; INFLIXIMAB; ARTHRITIS; PURPURA; THERAPY; EFALIZUMAB;

D O I：

10.1016/j.jaad.2008.12.001

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

Background: Thrombocytopenia has been reported to be associated with efalizumab therapy, but has only sporadically been reported with other anti-tumor necrosis factor alfa (TNF-alpha) agents. Objective: To describe the frequency of thrombocytopenia in a cohort of patients who underwent biological therapies for psoriasis. Methods. This was a retrospective observational study of 93 patients. Results: One hundred eighteen Courses of biological therapies were administered to 93 patients. Four of 67 patients who received anti-TNF-alpha agents developed drug-induced thrombocytopenia during treatment, compared with none of the 51 patients receiving efalizumab therapy. The platelet count recovered after Suspension of anti-TNF-alpha agents in 3 patients and relapsed after re-exposure in two patients. The overall estimated frequency of thrombocytopenia in our cohort was 4.30% (95% confidence interval [CI], 0% to 6.2%). Limitations: These findings should be validated in larger studies. Conclusions: Drug-induced thrombocytopenia is a potential side effect of anti-TNF-alpha agents. Immediate monitoring Of Platelet Counts is recommended if autoimmunity is suspected. (J Am Acad Dermatol 2009;60:781-5.)

引用

页码：781 / 785

页数：5

共 25 条

[1]

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis [J].

Day, R .

LANCET, 2002, 359 (9306) :540-541

[2]

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy:: a French national survey [J].

De Bandt, M ;

Sibilia, J ;

Le Loët, X ;

Prouzeau, S ;

Fautrel, B ;

Marcelli, C ;

Boucquillard, E ;

Siame, JL ;

Mariette, X .

ARTHRITIS RESEARCH & THERAPY, 2005, 7 (03) :R545-R551

[3]

Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome [J].

Driessen, R. J. B. ;

Berends, M. A. M. ;

Boezeman, J. B. ;

Van de Kerkhof, P. C. M. ;

de Jong, M. G. J. .

BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (05) :1098-1106

[4]

Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients [J].

Feletar, M ;

Brockbank, JE ;

Schentag, CT ;

Lapp, V ;

Gladman, DD .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (02) :156-161

[5]

Drug-induced thrombocytopenia: A systematic review of published case reports [J].

George, JN ;

Raskob, GE ;

Shah, SR ;

Rizvi, MA ;

Hamilton, SA ;

Osborne, S ;

Vondracek, T .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (11) :886-890

[6]

Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients [J].

Gerloni, V. ;

Pontikaki, I. ;

Gattinara, M. ;

Fantini, F. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (08) :1145-1152

[7]

Gladman DD, 1999, ARTHRITIS RHEUM-US, V42, P1785

[8]

A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis [J].

Hamaguchi, Masahide ;

Kawahito, Yutaka ;

Ishino, Hidetaka ;

Yoshida, Makie ;

Yoshikawa, Toshikazu .

CLINICAL RHEUMATOLOGY, 2007, 26 (06) :988-990

[9]

The immunologic basis for the treatment of psoriasis with new biologic agents [J].

Krueger, JG .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (01) :1-23

[10]

Infliximab: An alternative treatment for refractory immune thrombocytopenic purpura related to Crohn's disease? [J].

Lazaraki, Georgia ;

Metallidis, Simeon ;

Giannoulis, Kleanthis ;

Tarpagos, Anestis ;

Germanidis, Georgios .

INFLAMMATORY BOWEL DISEASES, 2007, 13 (11) :1452-1453

← 1 2 3 →